JP2014519852A5 - - Google Patents

Download PDF

Info

Publication number
JP2014519852A5
JP2014519852A5 JP2014517226A JP2014517226A JP2014519852A5 JP 2014519852 A5 JP2014519852 A5 JP 2014519852A5 JP 2014517226 A JP2014517226 A JP 2014517226A JP 2014517226 A JP2014517226 A JP 2014517226A JP 2014519852 A5 JP2014519852 A5 JP 2014519852A5
Authority
JP
Japan
Prior art keywords
composition
subject
administration
construct
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519852A (ja
JP6216921B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/043869 external-priority patent/WO2012178102A2/en
Publication of JP2014519852A publication Critical patent/JP2014519852A/ja
Publication of JP2014519852A5 publication Critical patent/JP2014519852A5/ja
Application granted granted Critical
Publication of JP6216921B2 publication Critical patent/JP6216921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517226A 2011-06-24 2012-06-22 アルファ−１抗トリプシン融合分子のための組成物、方法および使用 Expired - Fee Related JP6216921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500795P 2011-06-24 2011-06-24
US61/500,795 2011-06-24
PCT/US2012/043869 WO2012178102A2 (en) 2011-06-24 2012-06-22 Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016246746A Division JP2017079769A (ja) 2011-06-24 2016-12-20 アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Publications (3)

Publication Number Publication Date
JP2014519852A JP2014519852A (ja) 2014-08-21
JP2014519852A5 true JP2014519852A5 (enExample) 2015-08-06
JP6216921B2 JP6216921B2 (ja) 2017-11-01

Family

ID=47423247

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014517226A Expired - Fee Related JP6216921B2 (ja) 2011-06-24 2012-06-22 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2016246746A Withdrawn JP2017079769A (ja) 2011-06-24 2016-12-20 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2019012303A Pending JP2019058197A (ja) 2011-06-24 2019-01-28 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2020120557A Pending JP2020171316A (ja) 2011-06-24 2020-07-14 アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016246746A Withdrawn JP2017079769A (ja) 2011-06-24 2016-12-20 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2019012303A Pending JP2019058197A (ja) 2011-06-24 2019-01-28 アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2020120557A Pending JP2020171316A (ja) 2011-06-24 2020-07-14 アルファ−１抗トリプシン融合分子のための組成物、方法および使用

Country Status (7)

Country Link
US (5) US9938353B2 (enExample)
EP (2) EP3628327A1 (enExample)
JP (4) JP6216921B2 (enExample)
KR (2) KR20200044138A (enExample)
AU (4) AU2012272636A1 (enExample)
CA (1) CA2839917A1 (enExample)
WO (1) WO2012178102A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
PT2726092T (pt) * 2011-06-28 2019-10-08 Lp Inhibrx Polipéptidos de fusão serpina e métodos para a sua utilização
AU2013202648B2 (en) * 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
ES2799153T3 (es) * 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
CN105431165A (zh) * 2013-05-15 2016-03-23 莫尔研究应用有限公司 用于治疗心肺手术后的术后并发症的组合物和方法
EP3019188B1 (en) 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
JP6372562B2 (ja) * 2014-03-19 2018-08-15 株式会社安川電機 回転電機
WO2015191892A2 (en) 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES
WO2016144984A1 (en) * 2015-03-10 2016-09-15 Anvil Biosciences, Llc Serpins for the treatment of neuroinflammatory diseases
BR112019017438A2 (pt) * 2017-02-21 2020-05-05 Kamada Ltd uso de alfa-1-antitripsina
EP4321220B1 (en) * 2017-12-01 2025-10-29 CSL Behring LLC A1at for treating acute graft versus host disease after hematopoeitic cell transplantation
EP3802587A4 (en) * 2018-06-07 2022-03-23 Prottech Inc. PHARMACEUTICAL COMPOSITION WITH A FUSION PROTEIN AND THEIR USE
CN109251936B (zh) * 2018-09-20 2021-09-10 四川理工学院 一种光滑鳖甲丝氨酸蛋白酶抑制剂融合蛋白及制备与应用
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
TW202139997A (zh) * 2020-01-30 2021-11-01 美商維泰克斯製藥公司 α－１抗胰蛋白酶缺乏之治療方法
WO2021178448A1 (en) * 2020-03-02 2021-09-10 Motor Life Sciences, Llc Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity
KR102689456B1 (ko) * 2020-11-16 2024-07-29 경북대학교 산학협력단 알파-1 안티트립신을 포함하는 면역억제제에 의한 신장손상 예방 또는 치료용 조성물
WO2023198757A1 (en) * 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
WO2024261171A1 (en) * 2023-06-22 2024-12-26 Aatec Medical Gmbh Recombinant aat from yeast to treat transplants
EP4480493A1 (en) * 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung
WO2025014986A2 (en) * 2023-07-10 2025-01-16 Precigen, Inc. Therapy for alpha-1 antitrypsin deficiency
KR20250076724A (ko) * 2023-11-22 2025-05-30 아주대학교산학협력단 지속형 재조합 알파-1 항트립신 및 이의 용도

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
GB1472700A (en) 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
JPS5470241A (en) 1977-11-09 1979-06-05 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
GB2044760B (en) 1979-03-01 1983-03-23 Ono Pharmaceutical Co Guanidinobenzoic acid derivatives
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU577259B2 (en) 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
EP0169114B1 (fr) 1984-06-19 1991-01-16 Transgene S.A. Dérivés de l'alpha 1-antitrypsine humaine et procédé pour leur préparation
US4629567A (en) 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
US5157019A (en) 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US4829052A (en) 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5008242A (en) 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US4829054A (en) 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
US4857538A (en) 1987-11-30 1989-08-15 The Research Foundation Of State University Of New York New compounds for the study and treatment of microfilament organization in cells
US4963654A (en) 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
JP2568281B2 (ja) 1989-11-17 1996-12-25 原田工業株式会社 自動車用三波共用アンテナ
US5714140A (en) 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
DE69123960T2 (de) 1990-10-16 1997-05-07 John Lezdey Behandlung von entzündungen
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
JPH06509327A (ja) 1991-04-18 1994-10-20 ザ　ユー　エー　ビー　リサーチ　ファンデーション エラスターゼ抑制のための組成とその方法
US5175253A (en) 1991-04-24 1992-12-29 Washington University Binding peptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
AU3968193A (en) 1992-03-26 1993-10-21 Gensia, Inc. In vivo peptide therapy
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5604201A (en) 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
US5346886A (en) 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
JPH0827371A (ja) 1994-05-09 1996-01-30 Japan Carlit Co Ltd:The 紫外線及び赤外線吸収樹脂組成物
US6090786A (en) 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5514653A (en) 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5712117A (en) 1995-02-08 1998-01-27 Zymogenetics, Inc. Cytoplasmic antiproteinase-2 and coding sequences
ATE377006T1 (de) 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
EP0900791A1 (en) 1995-12-27 1999-03-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
JP3220169B2 (ja) 1996-12-06 2001-10-22 コーテック インコーポレーテッド セリンプロテアーゼ阻害剤
US6150332A (en) * 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
US6127145A (en) 1997-02-13 2000-10-03 Applied Phytologics, Inc. Production of α1 -antitrypsin in plants
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE19735587B4 (de) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6124257A (en) 1997-08-28 2000-09-26 Lezdey; John Method of treatment
US6964869B2 (en) 1998-07-13 2005-11-15 Wisconsin Alumni Research Foundation Method and composition for skin grafts
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
WO2000044390A1 (en) 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
GB9904421D0 (en) 1999-02-25 1999-04-21 Univ Edinburgh Telecommunications receiver
CA2364471A1 (en) * 1999-03-01 2000-09-08 Human Genome Sciences, Inc. Human serpin proteins
AU3864000A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU3719100A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US6174859B1 (en) 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
EP1231936A2 (en) 1999-10-27 2002-08-21 K-Quay Enterprises, LLC Methods and compositions for treatment of keratoconus using protease inhibitors
JP2003515325A (ja) 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
US6955845B1 (en) 2000-06-30 2005-10-18 Owens Corning Fiberglas Technology, Inc. Acoustical and thermal insulator
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP1355664A4 (en) 2001-01-04 2005-10-26 Vascular Biogenics Ltd METHODS INVOLVING MOLECULES ASSOCIATED WITH ATHEROSCLEROSIS PLATES AND COMPOSITIONS CONTAINING THESE MOLECULES FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
PL374045A1 (en) 2001-02-23 2005-09-19 Immunex Corporation Efficient recovery of correctly refolded proteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US6957148B2 (en) 2001-05-21 2005-10-18 The Board Of Regents, University Of Texas System Next-nearest-neighbor sequence determinants of antisense DNA
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US7001884B2 (en) 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease
WO2003000721A2 (en) 2001-06-22 2003-01-03 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7122641B2 (en) 2001-12-21 2006-10-17 Immunex Corporation Methods for purifying protein
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
EP1551834B1 (en) 2002-05-23 2010-08-25 Novartis Vaccines and Diagnostics, Inc. Substituted quinazolinone compounds
WO2004010989A1 (en) 2002-07-25 2004-02-05 Advances Life Sciences, Inc. Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals
EP1567183A4 (en) 2002-12-06 2006-08-09 Arriva Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR TREATING OTITIS MEDIA
US20040220242A1 (en) 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
AU2004289335A1 (en) 2003-11-12 2005-05-26 Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
US10022424B2 (en) 2004-05-12 2018-07-17 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
CA2654446C (en) * 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
WO2007079312A2 (en) 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
CL2007003411A1 (es) * 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
US20080199467A1 (en) 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
AU2008270951A1 (en) 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-1 antitrypsin having no significant serine protease inhibitor activity
WO2008138017A2 (en) * 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
CA2758445C (en) 2009-04-22 2016-02-16 Alteogen, Inc. In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
WO2011102845A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011156820A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for treatment of type 1 diabetes
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
PT2726092T (pt) * 2011-06-28 2019-10-08 Lp Inhibrx Polipéptidos de fusão serpina e métodos para a sua utilização
IN2013MN02442A (enExample) 2011-06-28 2015-06-12 Inhibrx Llc
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Similar Documents

Publication Publication Date Title
JP2014519852A5 (enExample)
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
JP2015504675A5 (enExample)
ES2257298T3 (es) Proteccion de peptidos terapeuticos endogenos contra la actividad de la peptidasa a traves de la conjugacion con componentes sanguineos.
CN102596217B (zh) 经修饰的血管活性肠肽
ES2332100T3 (es) Proteinas de fusion del fgf-21.
JP2020171316A (ja) アルファ−１抗トリプシン融合分子のための組成物、方法および使用
ES2393373T3 (es) Método para la producción de factor-I de crecimiento similar a la insulina
CN102482324B (zh) 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽
JP2007505643A5 (enExample)
JP2010516290A5 (enExample)
CN106632682A (zh) 融合蛋白ifn-elp及其应用
CN112673026B (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
ES2309992T3 (es) Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
KR20210132660A (ko) 천연 살해 세포를 자극하기 위한 조성물 및 방법
CN102482323A (zh) 新型肽及其应用
CN110172103B (zh) GLP-1类似物-Fc融合蛋白及其制备方法和用途
TWI300414B (en) Modified peptide yy and conjugates thereof
EP2846819A1 (en) Variants of tace pro-domain as tnf-a inhibitor and their medical use
JP2015533372A5 (enExample)
RU2012138553A (ru) Конъюгаты ig-i-поли(этиленгликоль)
US11807672B2 (en) Conjugates of islet neogenesis peptides and analogs, and methods thereof
CN106674353B (zh) 一种新的天花粉融合蛋白及其应用
CN117186239A (zh) 融合蛋白及其应用
CN118076373A (zh) 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物